Takhzyro Den europeiske union - norsk - EMA (European Medicines Agency)

takhzyro

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioødemer, arvelig - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Alunbrig Den europeiske union - norsk - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Livtencity Den europeiske union - norsk - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirusinfeksjoner - antivirale midler til systemisk bruk - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). det bør vurderes å offisielle retningslinjer for riktig bruk av antivirale midler.

Mepact Den europeiske union - norsk - EMA (European Medicines Agency)

mepact

takeda france sas - mifamurtide - osteosarkom - immunostimulants, - mepact er indisert hos barn, ungdom og unge for behandling av høyverdig resektabel ikke-metastatisk osteosarkom etter makroskopisk fullstendig kirurgisk reseksjon. det brukes i kombinasjon med postoperativ multi-agent kjemoterapi. sikkerhet og effekt har blitt vurdert i studier av pasienter fra 2 til 30 år ved første diagnose.

Ceprotin Den europeiske union - norsk - EMA (European Medicines Agency)

ceprotin

takeda manufacturing austria ag - humant protein c - purpura fulminans; protein c deficiency - antithrombotic agents - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.

Nycoplus C-vitamin 250 mg Norge - norsk - Statens legemiddelverk

nycoplus c-vitamin 250 mg

takeda as - askorbinsyre - tablett - 250 mg

Nycoplus Neo-Fer 9 mg/ ml Norge - norsk - Statens legemiddelverk

nycoplus neo-fer 9 mg/ ml

takeda as - jern(ii)fumarat - mikstur, suspensjon - 9 mg/ ml

Nycoplus B-Tonin 0.3 mg/ ml / 1 mg/ ml / 1.45 mg/ ml / 0.1 mg/ ml / 0.1 mg/ ml / 0.15 mg/ ml Norge - norsk - Statens legemiddelverk

nycoplus b-tonin 0.3 mg/ ml / 1 mg/ ml / 1.45 mg/ ml / 0.1 mg/ ml / 0.1 mg/ ml / 0.15 mg/ ml

takeda as - dekspantenol / nikotinamid / koffein / tiaminhydroklorid / pyridoksinhydroklorid / riboflavinnatriumfosfat - mikstur, oppløsning - 0.3 mg/ ml / 1 mg/ ml / 1.45 mg/ ml / 0.1 mg/ ml / 0.1 mg/ ml / 0.15 mg/ ml

Nycoplus B-Total 1.5 mg / 2 mg / 2 mg / 3 mg / 10 mg Norge - norsk - Statens legemiddelverk

nycoplus b-total 1.5 mg / 2 mg / 2 mg / 3 mg / 10 mg

takeda as - vitamin b1 / vitamin b2 / vitamin b6 / kalsiumpantotenat / nikotinamid - tablett, filmdrasjert - 1.5 mg / 2 mg / 2 mg / 3 mg / 10 mg

Pantoloc Control Den europeiske union - norsk - EMA (European Medicines Agency)

pantoloc control

takeda gmbh - pantoprazol - gastroøsofageal refluks - proton pumpen inhibitors - kortsiktig behandling av reflukssymptomer (f.eks. halsbrann, syreregurgitasjon) hos voksne.